Abstract 4480: SerRS is a Key Inhibitor of VEGFA Through Both Transcriptional and Translational Controls
Ze Liu,Yi Shi,Qian Zhang,Xianglei Yang
DOI: https://doi.org/10.1158/1538-7445.am2017-4480
IF: 11.2
2017-01-01
Cancer Research
Abstract:Abstract Vascular endothelial growth factor A (VEGFA) is the most important mediator of angiogenesis and a major target for cancer therapy. Recent studies from our lab revealed that seryl-tRNA synthetase (SerRS), by counteracting transcription factor c-Myc in the nucleus, is the crucial transcriptional repressor of VEGFA and a potent inhibitor of angiogenesis (1,2). Here we report that SerRS controls the expression of VEGFA not only in the nucleus but also in the cytoplasm through mediating its translational readthrough. Translational read-through of the VEGFA mRNA generates a novel isoform called VEGF-Ax that, compared with the non-readthrough isoform VEGF165, has a 22-amino acid C-terminal extension and much weakened angiogenic activity (3,4). Interestingly, serine was identified as the amino acid inserted in the place of the UGA stop codon during the read-through (3). In unpublished work, wWe findound that SerRS can bind to the 3’UTR region of the VEGFA mRNA. The binding anchors SerRS to charge serine onto tRNASec (the tRNA for the 21st amino acid selenocysteine that decodes the UGA stop codon), while preventing the charged serine from being modified into selenocysteine. SerRS binding also blocks the release factors (eRFs) from terminating translation at the stop codon. Therefore, SerRS is the key mediator of the translational readthrough that generates VEGF-Ax. Collectively, we have established that a member of the aminoacyl-tRNA synthetase family plays a critical role in regulating VEGF and angiogenesis through both transcriptional and translational controls. References 1. Xu X, Shi Y, Zhang HM, Swindell EC, Marshall AG, Guo M, Kishi S, Yang XL*. Unique domain appended to vertebrate tRNA synthetase is essential for vascular development. Nat Commun. 2012 Feb 21;3:681. 2. Shi Y, Xu X, Zhang Q, Fu G, Mo Z, Wang GS, Kishi S, Yang XL*. tRNA synthetase counteracts c-Myc to develop functional vasculature. Elife. 2014 Jun 17;3:e02349. 3. Eswarappa SM, Potdar AA, Koch WJ, Fan Y, Vasu K, Lindner D, Willard B, Graham LM, DiCorleto PE, Fox PL. Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell. 2014 Jun 19;157(7):1605-18. 4. Xin H, Zhong C, Nudleman E, Ferrara N. Evidence for Pro-angiogenic Functions of VEGF-Ax. Cell. 2016 Sep 22;167(1):275-284. Citation Format: Ze Liu, Yi Shi, Qian Zhang, Xianglei Yang. SerRS is a key inhibitor of VEGFA through both transcriptional and translational controls [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4480. doi:10.1158/1538-7445.AM2017-4480